PDR 001

Drug Profile

PDR 001

Alternative Names: PD-1 inhibitor - Novartis Oncology; PDR001

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Nasopharyngeal cancer; Neuroendocrine tumours
  • Phase I/II Solid tumours
  • Phase I Cancer; Hepatocellular carcinoma; Lymphoma

Most Recent Events

  • 25 Apr 2017 Phase-I clinical trials in Cancer (Combination therapy, Late-stage disease) in USA (IV) (NCT02947165)
  • 20 Apr 2017 Phase-I clinical trials for Hepatocellular carcinoma (Combination therapy, Late-stage disease, Inoperable/Unresectable) in Canada (IV) (NCT02988440)
  • 22 Mar 2017 Novartis plans a phase I trial of CJM 112 or LCL 161 in combination with PDR 001 and CJM 112 alone for Multiple myeloma (Second-line therapy) (NCT03111992)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top